褪黑素与年龄相关性黄斑变性风险
该回顾性队列研究基于美国TriNetX数据库,纳入50岁及以上无AMD史或非渗出性AMD史患者,分析褪黑素使用与AMD发生或进展的关联。结果显示,褪黑素使用与AMD发生风险降低(RR 0.42;95%CI 0.28-0.62)及非渗出性AMD进展为渗出性AMD风险降低(RR 0.44;95%CI 0.34-0.56)相关。
要点
- 在50岁及以上无AMD史人群中,褪黑素使用与AMD发生风险降低相关(RR 0.42;95%CI 0.28-0.62)。
- 在50岁及以上非渗出性AMD患者中,褪黑素使用与进展为渗出性AMD风险降低相关(RR 0.44;95%CI 0.34-0.56)。
- 60岁及以上和70岁及以上亚组结果与主分析一致。
核心结论
- 褪黑素使用与AMD发生风险降低相关(RR 0.42;95%CI 0.28-0.62)。
- 褪黑素使用与非渗出性AMD进展为渗出性AMD风险降低相关(RR 0.44;95%CI 0.34-0.56)。
- 生活方式因素可能影响该关联,这些发现为进一步研究褪黑素作为AMD预防性治疗的疗效提供了依据。
研究设计与样本
- 回顾性队列研究,数据来自TriNetX——美国全国性去标识化电子病历数据库,涵盖住院和门诊医疗机构。
- 数据查询时间为2023年12月4日至2024年3月19日;褪黑素用药代码查询时间段为2008年11月14日至2023年11月14日。
- 纳入50岁及以上、60岁及以上、70岁及以上无AMD史(AMD-naive组)或有非渗出性AMD史(非渗出性AMD组)的患者。
- 根据褪黑素用药代码分为褪黑素组和对照组,采用倾向性评分匹配(PSM)按人口学变量、合并症和非褪黑素催眠药使用进行匹配。
- 暴露定义为至少4次褪黑素记录,且每次记录间隔至少3个月。
主要发现
- 在50岁及以上AMD-naive组121523例患者中(褪黑素组4848例,PSM后4580例,平均(SD)年龄68.24(11.47)岁,女性2588例(56.5%);对照组116675例,PSM后4580例,平均(SD)年龄68.17(10.63)岁,女性2681例(58.5%)),褪黑素使用与AMD发生风险降低相关(RR 0.42;95%CI 0.28-0.62)。
- 在50岁及以上非渗出性AMD组66253例患者中(褪黑素组4350例,PSM后4064例,平均(SD)年龄80.21(8.78)岁,女性2482例(61.1%);对照组61903例,PSM后4064例,平均(SD)年龄80.31(8.03)岁,女性2531例(62.3%)),褪黑素使用与进展为渗出性AMD风险降低相关(RR 0.44;95%CI 0.34-0.56)。
- 在60岁及以上亚组中,AMD-naive组RR 0.36(95%CI 0.25-0.54),非渗出性AMD组RR 0.38(95%CI 0.30-0.49)。
- 在70岁及以上亚组中,AMD-naive组RR 0.35(95%CI 0.23-0.53),非渗出性AMD组RR 0.40(95%CI 0.31-0.51)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 生活方式因素可能影响了该关联。
- 这些发现为进一步研究褪黑素作为AMD预防性治疗的疗效提供了依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Melatonin has been shown to oppose several processes that are known to mediate age-related macular degeneration (AMD), but whether melatonin can confer benefits against AMD remains unclear. OBJECTIVE: To examine the association between melatonin supplementation and the risk of the development or progression of AMD. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study accessed data from TriNetX, a national database of deidentified electronic medical records from both inpatient and outpatient health care organizations across the US, between December 4, 2023, and March 19, 2024. Patients aged 50 years or older, 60 years or older, and 70 years or older with no history of AMD (AMD-naive group) and with a history of nonexudative AMD (nonexudative AMD group) were queried for instances of melatonin medication codes between November 14, 2008, and November 14, 2023. Patients were then classified into either a melatonin group or a control group based on the presence of medication codes for melatonin. Propensity score matching (PSM) was performed to match the cohorts based on demographic variables, comorbidities, and nonmelatonin hypnotic medication use. EXPOSURE: The presence of at least 4 instances of melatonin records that each occurred at least 3 months apart. MAIN OUTCOMES AND MEASURES: After PSM, the melatonin and the control cohorts were compared to evaluate the risk ratios (RRs) and the 95% CIs of having an outcome. For the AMD-naive group, the outcome was defined as a new diagnosis of any AMD, whereas for the nonexudative AMD group, the outcome was progression to exudative AMD. RESULTS: Among 121 523 patients in the melatonin-naive group aged 50 years or older (4848 in the melatonin cohort [4580 after PSM; mean (SD) age, 68.24 (11.47) years; 2588 female (56.5%)] and 116 675 in the control cohort [4580 after PSM; mean (SD) age, 68.17 (10.63) years; 2681 female (58.5%)]), melatonin use was associated with a reduced risk of developing AMD (RR, 0.42; 95% CI, 0.28-0.62). Among 66 253 patients aged 50 years or older in the nonexudative AMD group (4350 in the melatonin cohort [4064 after PSM; mean (SD) age, 80.21 (8.78) years; 2482 female (61.1%)] and 61 903 in the control cohort [4064 patients after PSM; mean (SD) age, 80.31 (8.03) years; 2531 female (62.3%)]), melatonin was associated with a reduced risk of AMD progression to exudative AMD (RR, 0.44; 95% CI, 0.34-0.56). The results were consistent among subsets of individuals aged 60 years or older (AMD-naive cohort: RR, 0.36 [95% CI, 0.25-0.54]; nonexudative AMD cohort: RR, 0.38 [95% CI, 0.30-0.49]) and 70 years or older (AMD-naive cohort: RR, 0.35 [95% CI, 0.23-0.53]; nonexudative AMD cohort: RR, 0.40 [95% CI, 0.31-0.51]). CONCLUSIONS AND RELEVANCE: Melatonin use was associated with a decreased risk of development and progression of AMD. Although lifestyle factors may have influenced this association, these findings provide a rationale for further research on the efficacy of using melatonin as a preventive therapy against AMD.
引用
- Jeong H, Shaia JK, Markle JC, et al. Melatonin and Risk of Age-Related Macular Degeneration. JAMA Ophthalmol. 2024. PMID: 38842832. doi:10.1001/jamaophthalmol.2024.1822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。